Important notice
Cancer Communications 2021年影响因子突破15分
Cancer Communications 进入2021年中科院期刊分区表医学1区和肿瘤学1区
Cancer Communications 入选中国科协发布的高质量肿瘤学科技期刊T1分级目录
Cancer Communications (CJC) 获评“2019中国最具国际影响力学术期刊”
Genomic information of children with malignant brain tumors for the prediction of length of hospitalization
Yichuan Liu, Hui-Qi Qu, Xiao Chang, Frank D Mentch, Haijun Qiu, Kenny Nguyen, Xiang Wang, Amir Hossein Saeidian, Deborah Watson, Joseph Glessner, Hakon Hakonarson
MFSD2A potentiates gastric cancer response to anti-PD-1 immunotherapy by reprogramming the tumor microenvironment to activate T cell response
Bin Zhang, Chun-Mei Wang, Hao-Xiang Wu, Feng Wang, Yang-Yang Chai, Ye Hu, Bing-Jing Wang, Zhou Yu, Rong-Hua Xia, Rui-Hua Xu, Xue-Tao Cao
Bin Zhang, Chun-Mei Wang, Hao-Xiang Wu, Feng Wang, Yang-Yang Chai, Ye Hu, Bing-Jing Wang, Zhou Yu, Rong-Hua Xia, Rui-Hua Xu, Xue-Tao Cao
Shujie Chen, Lina Fan, Yifeng Lin, Yadong Qi, Chaochao Xu, Qiwei Ge, Ying Zhang, Qiwen Wang, Dingjiacheng Jia, Lan Wang, Jianmin Si, Liangjing Wang
Novel CD123×CD33 bicistronic chimeric antigen receptor (CAR)-T therapy has potential to reduce escape from single-target CAR-T with no more hematotoxicity
Zhenzhen Wang, Yang Lu, Yu Liu, Junli Mou, Xiaoyu Liu, Manling Chen, Ying Wang, Yingxi Xu, Qing Rao, Haiyan Xing, Kejing Tang, Zheng Tian, Bing Wang, Wei Qi, Min Wang, Shaowei Qiu, Dongsheng Xiong, Jianxiang Wang
Uncovering the IL-1β-PCAF-NNT axis: A new player in ferroptosis and tumor immune evasion
Qidong Li, Boyi Gan
Worldwide trends in esophageal cancer survival, by sub-site, morphology, and sex: an analysis of 696,974 adults diagnosed in 60 countries during 2000-2014 (CONCORD-3)
Melissa Matz, Mikhail Valkov, Mario ?ekerija, Sabine Luttman, Adele Caldarella, Michel P Coleman, Claudia Allemani, the CONCORD Working Group
An HGF-dependent positive feedback loop between bladder cancer cells and fibroblasts mediates lymphangiogenesis and lymphatic metastasis
Yuting Li, Hanhao Zheng, Yuming Luo, Yan Lin, Mingjie An, Yao Kong, Yue Zhao, Yina Yin, Le Ai, Jian Huang, Changhao Chen
Combined local therapy and CAR-GPC3 T-cell therapy in advanced hepatocellular carcinoma: a proof-of-concept treatment strategy
Yaoping Shi, Donghua Shi, Jiachang Chi, Dan Cui, Xiaoyin Tang, Yan Lin, Siying Wang, Zonghai Li, Haojie Jin, Bo Zhai
Targeting histone deacetylase suppresses tumor growth through eliciting METTL14-modified m6A RNA methylation in ocular melanoma
Ai Zhuang, Xiang Gu, Tongxin Ge, Shaoyun Wang, Shengfang Ge, Peiwei Chai, Renbing Jia, Xianqun Fan
The MonarchE trial: improving the clinical outcome in HR+/HER2 — early breast cancer: recent results and next steps
Fran?ois Bertucci, Pascal Finetti, Emilie Mamessier, Alexandre De Nonneville
Gastric cancer |
|
Edited by Yun Dai and Li Yan |
This thematic series discusses the molecular classifications of gastric cancer by the Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG) as well as the implications in personalized therapeutic choices; discusses the evolution of gastric surgery and presents perspectives on surgical techniques in treating gastric cancer; and reviews current and emerging targeted agents as well as immunotherapies in treating gastric cancer. With these advancements in molecular characterization, surgical intervention, and targeted and immunotherapies, gastric cancer will enter a personalized medicine era in the next 5 years.
|
- - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Tumor angiogenesis |
|
Edited by Francesco Pezzella
|
Forming efficient vasculature network, also known as tumor angiogenesis, is a critical hallmark in tumor development. Explorations on its underlying molecular mechanisms have resulted in several novel anti-cancer drugs. However, the modest survival benefits from anti-angiogenic therapy have forced us to revisit our understanding on tumor angiogenesis. In this special issue, world-leading experts have contributed their critical thoughts to reveal alternative tumor angiogenesis approaches and potential treatment targets.
|
- - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Lung cancer |
|
 Edited by Lin Yan and Wei Zhang
|
Lung cancer accounts for approximately 21% of worldwide cancer deaths and a staggering 1.6 million new cases are diagnosed every year. In China, lung cancer has become a particularly challenging disease because of air pollution and smoking. This thematic series discusses the proper use of targeted agents in treating lung cancer, reviews the application of biomarkers in clinical management and drug development, and analyzes the unique challenges in developing novel drugs for lung cancer in China.
|
CC adopts ScholarOne Manuscripts
to manage its submissions from Nov.1, 2019
Submission Guidelines
Reference style for
CC is now published by Wiley
© Cancer Communications
651 Dongfeng Road East,Guangzhou 510060, P.R.China
